Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Kontoghiorghes, G. J., Efstathiou, A., Kleanthous, M., Michaelides, Y., & Kolnagou, A. Hemoglobin, 33(5):386–397, 2009. Place: Englanddoi bibtex @article{kontoghiorghes_riskbenefit_2009,
title = {Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.},
volume = {33},
issn = {1532-432X 0363-0269},
doi = {10.3109/03630260903217141},
language = {eng},
number = {5},
journal = {Hemoglobin},
author = {Kontoghiorghes, George J. and Efstathiou, Aglaia and Kleanthous, Marios and Michaelides, Yiannis and Kolnagou, Anita},
year = {2009},
pmid = {19814684},
note = {Place: England},
keywords = {Animals, Antioxidants/*therapeutic use, Benzoates/therapeutic use, Chelation Therapy, Copper/metabolism, Deferasirox, Deferiprone, Deferoxamine/therapeutic use, Free Radicals/metabolism, Humans, Iron Chelating Agents/*therapeutic use, Iron Overload/complications/*drug therapy, Iron/metabolism, Oxidative Stress/*drug effects, Pyridones/*therapeutic use, Risk Assessment, Siderophores/therapeutic use, Thalassemia/*drug therapy, Triazoles/therapeutic use},
pages = {386--397},
}
Downloads: 0
{"_id":"5apzE7LtBWPAyw68q","bibbaseid":"kontoghiorghes-efstathiou-kleanthous-michaelides-kolnagou-riskbenefitassessmentadvantagesoverotherdrugsandtargetingmethodsintheuseofdeferiproneasapharmaceuticalantioxidantinironloadingandnonironloadingconditions-2009","author_short":["Kontoghiorghes, G. J.","Efstathiou, A.","Kleanthous, M.","Michaelides, Y.","Kolnagou, A."],"bibdata":{"bibtype":"article","type":"article","title":"Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.","volume":"33","issn":"1532-432X 0363-0269","doi":"10.3109/03630260903217141","language":"eng","number":"5","journal":"Hemoglobin","author":[{"propositions":[],"lastnames":["Kontoghiorghes"],"firstnames":["George","J."],"suffixes":[]},{"propositions":[],"lastnames":["Efstathiou"],"firstnames":["Aglaia"],"suffixes":[]},{"propositions":[],"lastnames":["Kleanthous"],"firstnames":["Marios"],"suffixes":[]},{"propositions":[],"lastnames":["Michaelides"],"firstnames":["Yiannis"],"suffixes":[]},{"propositions":[],"lastnames":["Kolnagou"],"firstnames":["Anita"],"suffixes":[]}],"year":"2009","pmid":"19814684","note":"Place: England","keywords":"Animals, Antioxidants/*therapeutic use, Benzoates/therapeutic use, Chelation Therapy, Copper/metabolism, Deferasirox, Deferiprone, Deferoxamine/therapeutic use, Free Radicals/metabolism, Humans, Iron Chelating Agents/*therapeutic use, Iron Overload/complications/*drug therapy, Iron/metabolism, Oxidative Stress/*drug effects, Pyridones/*therapeutic use, Risk Assessment, Siderophores/therapeutic use, Thalassemia/*drug therapy, Triazoles/therapeutic use","pages":"386–397","bibtex":"@article{kontoghiorghes_riskbenefit_2009,\n\ttitle = {Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.},\n\tvolume = {33},\n\tissn = {1532-432X 0363-0269},\n\tdoi = {10.3109/03630260903217141},\n\tlanguage = {eng},\n\tnumber = {5},\n\tjournal = {Hemoglobin},\n\tauthor = {Kontoghiorghes, George J. and Efstathiou, Aglaia and Kleanthous, Marios and Michaelides, Yiannis and Kolnagou, Anita},\n\tyear = {2009},\n\tpmid = {19814684},\n\tnote = {Place: England},\n\tkeywords = {Animals, Antioxidants/*therapeutic use, Benzoates/therapeutic use, Chelation Therapy, Copper/metabolism, Deferasirox, Deferiprone, Deferoxamine/therapeutic use, Free Radicals/metabolism, Humans, Iron Chelating Agents/*therapeutic use, Iron Overload/complications/*drug therapy, Iron/metabolism, Oxidative Stress/*drug effects, Pyridones/*therapeutic use, Risk Assessment, Siderophores/therapeutic use, Thalassemia/*drug therapy, Triazoles/therapeutic use},\n\tpages = {386--397},\n}\n","author_short":["Kontoghiorghes, G. J.","Efstathiou, A.","Kleanthous, M.","Michaelides, Y.","Kolnagou, A."],"key":"kontoghiorghes_riskbenefit_2009","id":"kontoghiorghes_riskbenefit_2009","bibbaseid":"kontoghiorghes-efstathiou-kleanthous-michaelides-kolnagou-riskbenefitassessmentadvantagesoverotherdrugsandtargetingmethodsintheuseofdeferiproneasapharmaceuticalantioxidantinironloadingandnonironloadingconditions-2009","role":"author","urls":{},"keyword":["Animals","Antioxidants/*therapeutic use","Benzoates/therapeutic use","Chelation Therapy","Copper/metabolism","Deferasirox","Deferiprone","Deferoxamine/therapeutic use","Free Radicals/metabolism","Humans","Iron Chelating Agents/*therapeutic use","Iron Overload/complications/*drug therapy","Iron/metabolism","Oxidative Stress/*drug effects","Pyridones/*therapeutic use","Risk Assessment","Siderophores/therapeutic use","Thalassemia/*drug therapy","Triazoles/therapeutic use"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/4516419/collections/XQQRG67P/items?key=iUGtZ5FwZ23zKgsOTKK1Vgda&format=bibtex&limit=100","dataSources":["6iCaXTjNkdcqEW6gd","MnayAXw3qciX87bz7"],"keywords":["animals","antioxidants/*therapeutic use","benzoates/therapeutic use","chelation therapy","copper/metabolism","deferasirox","deferiprone","deferoxamine/therapeutic use","free radicals/metabolism","humans","iron chelating agents/*therapeutic use","iron overload/complications/*drug therapy","iron/metabolism","oxidative stress/*drug effects","pyridones/*therapeutic use","risk assessment","siderophores/therapeutic use","thalassemia/*drug therapy","triazoles/therapeutic use"],"search_terms":["risk","benefit","assessment","advantages","over","drugs","targeting","methods","use","deferiprone","pharmaceutical","antioxidant","iron","loading","non","iron","loading","conditions","kontoghiorghes","efstathiou","kleanthous","michaelides","kolnagou"],"title":"Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.","year":2009}